PDE4A and Alzheimer disease: Crisaborole (eucrisa) addresses AD by acting as a non-steroidal anti-inflammatory agent and a PDE4 inhibitor, reducing pro-inflammatory cytokine and chemokine levels by upregulating intracellular adenosine monophosphate [73,75-76].